Previous close | 8.69 |
Open | 9.84 |
Bid | 8.75 x 500 |
Ask | 9.24 x 500 |
Day's range | 8.83 - 9.94 |
52-week range | 1.52 - 11.25 |
Volume | |
Avg. volume | 3,555,577 |
Market cap | 6.472B |
Beta (5Y monthly) | -1.13 |
PE ratio (TTM) | 24.26 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday. Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expre
Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab, sold under brand name Keytruda, in a Phase 3 trial involving lung-cancer patients.
Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript May 1, 2024 Summit Therapeutics Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06. SMMT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies […]